180 Life Sciences Corp (ATNF)

Overview News Price History Discussions Forecast Stock Split

180 Life Sciences Corp stock is currently priced at $1.95, with a 24-hour trading volume of 73,160. It has seen a +4.71% increased in the last 24 hours and a -40.83% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.79 pivot point. If it approaches the $2.11 resistance level, significant changes may occur.

180 Life Sciences Corp Stock (ATNF) Financials Data

180 Life Sciences Corp (ATNF) Net Income 2024

ATNF net income (TTM) was -$19.94 million for the quarter ending December 31, 2023, a +48.52% increase year-over-year.

180 Life Sciences Corp (ATNF) Cash Flow 2024

ATNF recorded a free cash flow (TTM) of -$10.92 million for the quarter ending December 31, 2023, a +9.94% increase year-over-year.

180 Life Sciences Corp (ATNF) Earnings per Share 2024

ATNF earnings per share (TTM) was -$64.27 for the quarter ending December 31, 2023, a +82.40% growth year-over-year.

180 Life Sciences Corp Stock (ATNF) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Feldmann Marc	Director	Dec 15 '23	Sale	0.19	25,000	4,700	115,497
STEINMAN LAWRENCE	Director	Jun 01 '23	Buy	1.23	18,000	22,068	48,129
McGovern Jr. Donald A.	Director	May 31 '23	Buy	1.15	10,000	11,470	30,099
McGovern Jr. Donald A.	Director	May 19 '23	Buy	1.16	5,000	5,800	20,099
Woody James N.	Chief Executive Officer	May 18 '23	Buy	1.03	40,000	41,200	41,888
McGovern Jr. Donald A.	Director	May 18 '23	Buy	1.05	10,000	10,500	15,099
Marrone Pamela G	Director	May 18 '23	Buy	1.06	7,082	7,507	12,469
Pamir Ozan	CFO	May 18 '23	Buy	1.01	5,162	5,214	8,983

180 Life Sciences Corp Stock (ATNF) Latest News

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire Inc.

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

GlobeNewswire Inc.

Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

US Stocks Higher; Inflation Rate Increases To 3.4% In December

Benzinga

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Benzinga

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.